Insulin Cost Caps and Pharmacoequity
https://jamanetwork.com/journals/jama/fullarticle/2850129

Diabetes incidence is rising in the US, with more than 40 million US residents living with this condition. Diabetes morbidity and mortality are unequally distributed, and new diagnoses are higher among American Indian/Alaska Native, Black, and Hispanic adults, compared with White adults. Managing prescription medications is critical to reducing diabetes morbidity, as is controlling risk factors and associated comorbid conditions. However, the cost of pharmacologic therapy has increased substantially, driven in part by the growing use of newer glucose-lowering agents. The high cost of these medications comprises a substantial portion of diabetes-related health care expenditure for individuals with diabetes and may result in restrictive coverage by health plans insuring enrollees with diabetes, further limiting access to care. The out-of-pocket costs faced by patients are particularly burdensome, because patients also face the consequences of adverse downstream outcomes that result from reduced medication adherence due to costs.

Insulin Costs and Use After the Inflation Reduction Act Out-of-Pocket Cap
https://jamanetwork.com/journals/jama/fullarticle/2850128

This interrupted time series analysis uses Medicare Part D data from January 2021 through December 2023 to measure changes in insulin cost and use after the Inflation Reduction Act $35 cap on out-of-pocket insulin costs, overall and for insulin users with previously high out-of-pocket cost.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
https://jamanetwork.com/journals/jama/fullarticle/2850143

This randomized clinical trial compares the efficacy and safety of a 9-mg dose of mazdutide vs placebo in Chinese adults with obesity.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850142

This study evaluated whether a once-weekly, 9-mg dose of mazdutide (combined with a reduced calorie diet and increased physical activity) leads to effective and safe weight reduction in Chinese adults with obesity (body mass index [BMI] ≥30) compared with placebo.

Cognition After Postoperative Delirium
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850109

Postoperative delirium is common in older adults, but some of its long-term consequences remain debated. Its association with adverse outcomes is well established, including longer hospital stays, functional decline, institutionalization, and mortality. A more challenging question is whether delirium itself contributes to later cognitive decline or if it mainly identifies patients who already have frailty, have a health record that is medically complex, and are likely to become ill again. These competing explanations have distinct implications for care, including what we tell patients and families at discharge, how we plan follow-up, and how much emphasis we place on delirium prevention. In this issue of JAMA Internal Medicine, Hshieh et al provide data that help advance this debate.

Evaluating Inflammatory Joint Pain in Older Adults
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850108

This Clinical Insights discusses inflammatory arthritis in older adults and offers practical guidance.

Survivors of Cyanotic Congenital Heart Disease: A Review
https://jamanetwork.com/journals/jama/fullarticle/2850177

This Review discusses the pathophysiology of cardiovascular complications in adults with cyanotic congenital heart disease after early management and examines late complications and management strategies.

Missing Funding/Support and Role of the Funder Statement
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850077

In the Original Investigation titled “Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis,” published online on May 4, 2026, the Funding/Support and Role of the Funder/Sponsor acknowledgments were missing in the Article Information. The work was funded by a grant from Parkinson’s UK. This information has been added, in addition to the Role of the Funder/Sponsor. This article has been corrected online.

Self-Reported Seizure Durations
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850076

This cohort study examines the range of self-reported seizure durations from more than 18 000 children and adults.

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850075

This cross-sectional study investigates how genetic variants and neuropathology are associated with clinical features and diagnostic accuracy in movement disorders.

Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850074

This randomized clinical trial evaluates whether a reperfusion-guided systolic blood pressure control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke.

High-Dose Vitamin C in Burns
https://jamanetwork.com/journals/jama/fullarticle/2850393

In this issue of JAMA, Stoppe and colleagues present the results of an international randomized clinical trial that provides evidence that high-dose intravenous vitamin C does not improve outcomes in patients with large burns. The data from the VICTORY trial even suggest that use of vitamin C in patients with large burns might increase mortality. This well-designed study had strict criteria for stopping based on futility or harm. It is clear that the possibility of vitamin C improving outcomes in major burns is extremely low.

High-Dose Intravenous Vitamin C in Severe Burn Injury
https://jamanetwork.com/journals/jama/fullarticle/2850392

This international randomized clinical trial evaluates the efficacy of high-dose intravenous vitamin C in reducing 28-day mortality and persistent organ dysfunction (dependence on mechanical ventilation, kidney replacement therapy, or vasopressor/inotrope support at day 28) in patients with severe burn injury.

High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850391

The objective of this study was to determine whether high-dose intravenous vitamin C improves a composite of 28-day mortality and persistent organ dysfunction in patients with severe burn injury.

Neurological Manifestations in Adult Survivors of Ebola Virus Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850237

This cohort study evaluates the neurological health of adult survivors of Ebola virus disease over the course of a 7-year follow-up.

Cost Offset With Quadruple Therapy for Heart Failure
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850258

This economic evaluation examines Medicare-linked registry data to estimate the 1-year health care cost offset and net cost associated with using quadruple guideline-directed medical therapy after hospitalization for heart failure with reduced ejection fraction.

Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850257

In this issue of JAMA Cardiology, Vossen et al report the results of a randomized clinical trial investigating whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) at a daily dose of 360 µg would delay progression of coronary artery calcification. Among 180 patients with baseline coronary artery calcium (CAC) scores of 50 to 400 Agatston units (AU), they observed a small but statistically significant slowing of CAC progression, measured as either AU or calcium mass score.

Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850256

This randomized clinical trial evaluates the progression of coronary artery calcification compared with placebo over a 2-year period.

Will the Bicarbonate for In-Hospital Cardiac Arrest Trial Change Practice?
https://jamanetwork.com/journals/jama/fullarticle/2850406

In this issue of JAMA, Granfeldt and colleagues share results of the Bicarbonate for In-Hospital Cardiac Arrest randomized clinical trial comparing routine administration of sodium bicarbonate with placebo during attempted resuscitation of 779 patients with in-hospital cardiac arrest. The physiological rationale for administering sodium bicarbonate is to temporarily reduce the profound metabolic acidosis that develops during cardiac arrest to reverse myocardial depression and improve catecholamine action. Sodium bicarbonate is hypertonic and may increase intravascular volume. The primary outcome of return of spontaneous circulation was not different after sodium bicarbonate (39%) relative to placebo (37%). The intervention also did not change secondary outcomes, including organ dysfunction in the first 72 hours, 30-day survival (12% vs 9%), functional scores, or quality-of-life scores. Among patients who survived, those in the sodium bicarbonate group had higher pH and blood bicarbonate values, demonstrating successful delivery of the intervention.

Sodium Bicarbonate for In-Hospital Cardiac Arrest
https://jamanetwork.com/journals/jama/fullarticle/2850405

This randomized clinical trial examines whether administration of sodium bicarbonate during in-hospital cardiac arrest increases return of spontaneous circulation as well as survival and survival with a favorable neurologic outcome.